Table 1. Characteristics of included patients.
| Included Concomitant FT and viral load | Not included | Significance P value | |
| Number of patients | 1074 | 226 | |
| Characteristics | |||
| Age at baseline (years) mean (SD) | 40.7 (12.6) | 41.8 (13.7) | 0.24 |
| Male (%) | 738 (69) | 180 (80) | 0.001 |
| Female (%) | 336 (31) | 46 (20) | |
| Body Mass Index (kg/m2) | 23.9 (4.3) | 22.8 (3.9) | 0.006 |
| Ethnic origin (%) | 0.0005 | ||
| Caucasian | 280 (26) | 73 (32) | |
| African | 503 (47) | 103 (46) | |
| Asian | 291 (27) | 50 (22) | |
| Source of infection (%) | 0.02 | ||
| Transfusion | 53 (4.9) | 2 (0.9) | |
| IV drug | 13 (1.2) | 3 (1.3) | |
| Other or unknown | 1008 (93.9) | 221 (97.8) | |
| Alcohol (g per day) (%) | (n = 1055) | (n = 220) | 0.003 |
| 0 | 869 (82) | 166 (75) | |
| 0–50 | 153 (15) | 37 (17) | |
| Over 50 | 33 (3) | 17 (8) | |
| At least one co-infection | 167 (15.5) | 40 (17.7) | 0.42 |
| Coinfection HIV (%) | 61 (5.7) | 22 (9.7) | 0.02 |
| Coinfection HCV (%) | 62 (5.8) | 11 (4.9) | 0.59 |
| Coinfection Delta | 75 (7.0) | 15 (6.6) | 0.85 |
| Baseline viral load (KUI/ml) (SD) | 4462 (56462) (n = 1074) | 10281 (26994) (n = 203) | 0.15 |
| Low <200 IU/ml | 683 (63.6%) | 89 (43.8%) | P<0.001 |
| Intermediate 200–20,000 IU/ml | 169 (15.7%) | 15 (7.4%) | |
| High >20,000 IU/ml | 222 (20.7%) | 99 (48.8%) | |
| Risk factors | |||
| Diabetes (%) | 44 (4.1) | 9 (4.0) | 0.94 |
| Renal failure (%) | 34 (3.2) | 9 (4.0) | 0.53 |
| Simultaneous biopsies (n) | 97 | 62 | |
| Advanced fibrosis F2F3F4 (%) | 33 (33%) | 32 (52%) | 0.03 |
| Moderate-severe activity A2A3 (%) | 19 (20%) | 26 (43%) | 0.002 |
| Steatosis >5% (%) | 47/97 (49) | 19/62 (31) | 0.03 |
| All biopsies (n) | 505 | 132 | |
| Advanced fibrosis F2F3F4 (%) | 191 (38%) | 60 (46%) | 0.11 |
| Moderate-severe activity A2A3 (%) | 144 (29%) | 47 (36%) | 0.11 |
| Steatosis >5% (%) | 212/434 (49%) | 49/104 (47%) | 0.75 |
| Biomarkers (SD) | |||
| Number performed | 1074 | 0 | |
| ALT UI/L | 80 (270) (n = 1074) | 126 (283) (n = 226) | 0.02 |
| Total Bilirubin umoles/L | 19.9 (53.3) (n = 1074) | 39.9 (103.7) (n = 98) | 0.001 |
| GGT IU/L | 52.3 (95.8) (n = 1074) | 106.4 (159.4) (n = 94) | <0.001 |
| Alpha2 macroglobulin g/L | 2.22 (0.76) | NP | |
| ApoA1 g/L | 1.45 (0.35) | NP | |
| Haptoglobin g/l | 0.87 (0.55) | NP | |
| FibroTest (0.00–1.00) | 0.34 (0.26) | NP | |
| ActiTest (0.00–1.00) | 0.26 (0.25) | NP | |
| Duration prospective follow-up | 2.5 (0.5) | 4.8 (0.3) | |
| Duration retrospective follow-up | 5.2 (0.2) | 3.0 (0.4) | |
| Treated for HBV | 646 (60%) | 102 (45%) | <0.001 |
| Complications retrospective follow-up | 87 (8.1%) | 23 (10.2%) | 0.30 |
| Complications (not lethal) prospective follow-up | 14 (1.3%) | 29 (12.8%) | <0.001 |
| Death related to HBV | 27 (2.5%) | 23 (10.2%) | <0.001 |
| Death or complications related to HBV | 41 (3.8%) | 52 (23.0%) | <0.001 |
| Death not related to HBV | 9 (0.8%) | 7 (3.1%) | 0.005 |
| Overall death | 36 (3.4%) | 30 (13.3%) | <0.001 |
NP = Not performed.